{"id":"W4282970409","doi":"10.2217/fon-2022-0380","title":"A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an <i>in situ</i> vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Oncology; Cystectomy; Bladder cancer; Internal medicine; Radiation therapy; Clinical trial; Cisplatin; Neoadjuvant therapy; Immune checkpoint; Chemotherapy; Cancer; Immunotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001151831,0.0002515893,0.0009839727,0.0001484836,0.0002521281,0.00001122505,0.0001689134,0.0002081844,0.0002254623],"category_scores_gemma":[0.0001330215,0.0001702283,0.0002209561,0.0002617335,0.00003158071,0.00008774545,0.00007304714,0.000469211,0.000001607158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001786526,"about_ca_system_score_gemma":0.0006578189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001249967,"about_ca_topic_score_gemma":0.0001643659,"domain_scores_codex":[0.9973736,0.0006167334,0.0009313595,0.0004838975,0.0002681704,0.0003262814],"domain_scores_gemma":[0.9983121,0.0006032025,0.0004332161,0.0004320419,0.00007599318,0.0001434225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8176215,0.0123945,0.0007249918,0.00002152614,0.000294048,0.00005405147,0.001091943,0.000001039476,0.002389449,0.0001059544,0.004485502,0.1608155],"study_design_scores_gemma":[0.6868937,0.1508393,0.001456367,0.000007308576,0.0003436689,0.00009508879,0.0003121554,0.00007478007,0.0004088691,0.0001894889,0.1592592,0.0001201817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781852,0.002160587,0.00001114138,0.01059918,0.002884126,0.00554,0.00007494957,0.00002918946,0.0005155781],"genre_scores_gemma":[0.9898643,0.001266938,0.0001303595,0.002909056,0.004456752,0.0008890537,0.0002354291,0.00004202907,0.0002060136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1606954,"threshold_uncertainty_score":0.6941708,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04402021379365379,"score_gpt":0.4166381891270673,"score_spread":0.3726179753334135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}